M-A Fitzcharles1,2, C Baerwald3, J Ablin4, W Häuser5,6. 1. Division of Rheumatology, McGill University Health Centre, Quebec, Canada. 2. Alan Edwards Pain Management Unit, McGill University Health Center, Quebec, Canada. 3. Department Internal Medicine, Neurology and Dermatology, Clinic for Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig, Germany. 4. Institute of Rheumatology, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Department Internal Medicine I, Klinikum Saarbrücken, Winterberg 1, Saarbrucken, Germany. whaeuser@klinikum-saarbruecken.de. 6. Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany. whaeuser@klinikum-saarbruecken.de.
Abstract
BACKGROUND: In the absence of an ideal treatment for chronic pain associated with rheumatic diseases, there is interest in the potential effects of cannabinoid molecules, particularly in the context of global interest in the legalization of herbal cannabis for medicinal use. METHODS: A systematic search until April 2015 was conducted in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, www.cannabis-med.org and clinicaltrials.gov for randomized controlled trials with a study duration of at least 2 weeks and at least ten patients per treatment arm with herbal cannabis or pharmaceutical cannabinoid products in fibromyalgia syndrome (FMS), osteoarthritis (OA), chronic spinal pain, and rheumatoid arthritis (RA) pain. Outcomes were reduction of pain, sleep problems, fatigue and limitations of quality of life for efficacy, dropout rates due to adverse events for tolerability, and serious adverse events for safety. The methodology quality of the randomized controlled trials (RCTs) was evaluated by the Cochrane Risk of Bias Tool. RESULTS: Two RCTs of 2 and 4 weeks duration respectively with nabilone, including 71 FMS patients, one 4-week trial with nabilone, including 30 spinal pain patients, and one 5-week study with tetrahydrocannbinol/cannabidiol, including 58 RA patients were included. One inclusion criterion was pain refractory to conventional treatment in three studies. No RCT with OA patients was found. The risk of bias was high for three studies. The findings of a superiority of cannabinoids over controls (placebo, amitriptyline) were not consistent. Cannabinoids were generally well tolerated despite some troublesome side effects and safe during the study duration. CONCLUSIONS: Currently, there is insufficient evidence for recommendation for any cannabinoid preparations for symptom management in patients with chronic pain associated with rheumatic diseases.
BACKGROUND: In the absence of an ideal treatment for chronic pain associated with rheumatic diseases, there is interest in the potential effects of cannabinoid molecules, particularly in the context of global interest in the legalization of herbal cannabis for medicinal use. METHODS: A systematic search until April 2015 was conducted in Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, www.cannabis-med.org and clinicaltrials.gov for randomized controlled trials with a study duration of at least 2 weeks and at least ten patients per treatment arm with herbal cannabis or pharmaceutical cannabinoid products in fibromyalgia syndrome (FMS), osteoarthritis (OA), chronic spinal pain, and rheumatoid arthritis (RA) pain. Outcomes were reduction of pain, sleep problems, fatigue and limitations of quality of life for efficacy, dropout rates due to adverse events for tolerability, and serious adverse events for safety. The methodology quality of the randomized controlled trials (RCTs) was evaluated by the Cochrane Risk of Bias Tool. RESULTS: Two RCTs of 2 and 4 weeks duration respectively with nabilone, including 71 FMS patients, one 4-week trial with nabilone, including 30 spinal painpatients, and one 5-week study with tetrahydrocannbinol/cannabidiol, including 58 RApatients were included. One inclusion criterion was pain refractory to conventional treatment in three studies. No RCT with OApatients was found. The risk of bias was high for three studies. The findings of a superiority of cannabinoids over controls (placebo, amitriptyline) were not consistent. Cannabinoids were generally well tolerated despite some troublesome side effects and safe during the study duration. CONCLUSIONS: Currently, there is insufficient evidence for recommendation for any cannabinoid preparations for symptom management in patients with chronic pain associated with rheumatic diseases.
Authors: Andrew R Moore; Christopher Eccleston; Sheena Derry; Phillip Wiffen; Rae F Bell; Sebastian Straube; Henry McQuay Journal: Pain Date: 2010-06-02 Impact factor: 6.961
Authors: Frederick Wolfe; Daniel J Clauw; Mary-Ann Fitzcharles; Don L Goldenberg; Winfried Häuser; Robert S Katz; Philip Mease; Anthony S Russell; I Jon Russell; John B Winfield Journal: J Rheumatol Date: 2011-02-01 Impact factor: 4.666
Authors: Peter A Ste-Marie; Mary-Ann Fitzcharles; Ann Gamsa; Mark A Ware; Yoram Shir Journal: Arthritis Care Res (Hoboken) Date: 2012-08 Impact factor: 4.794
Authors: M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice Journal: Proc Natl Acad Sci U S A Date: 1990-03 Impact factor: 11.205
Authors: Michael C Lee; Markus Ploner; Katja Wiech; Ulrike Bingel; Vishvarani Wanigasekera; Jonathan Brooks; David K Menon; Irene Tracey Journal: Pain Date: 2013-01 Impact factor: 6.961
Authors: Nicholas T Vozoris; Zhan Yao; Ping Li; Peter C Austin; Anne L Stephenson; Sudeep S Gill; Denis E O'Donnell; Andrea S Gershon; Paula A Rochon Journal: Drugs Aging Date: 2019-11 Impact factor: 3.923
Authors: C Sommer; R Alten; K-J Bär; M Bernateck; W Brückle; E Friedel; P Henningsen; F Petzke; T Tölle; N Üçeyler; A Winkelmann; W Häuser Journal: Schmerz Date: 2017-06 Impact factor: 1.107
Authors: G Michael Allan; Caitlin R Finley; Joey Ton; Danielle Perry; Jamil Ramji; Karyn Crawford; Adrienne J Lindblad; Christina Korownyk; Michael R Kolber Journal: Can Fam Physician Date: 2018-02 Impact factor: 3.275